A Protocol for the Use of Chlorhexidine Gluconate Saturation for the Reduction of Dental Biofilm Formation on Polymethylmethacrylate Restoration - Full Text View

A Protocol for the Use of Chlorhexidine Gluconate Saturation for the Reduction of Dental Biofilm Formation on Polymethylmethacrylate Restoration

This study has been completed.

Sponsored by:	Hadassah Medical Organization
Information provided by:	Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00259181

Purpose

Chlorhexidine gluconate (CHX), as an anti plaque agent, is commonly used with a variety of products. In this study we, the investigators at Hadassah Medical Organization, intend to examine the efficacy of a single dip in CHX of provisional restoration prior to oral cementation. If the protocol is effective, we intend to calibrate it and recommend clinical use of the protocol. The examination of biofilm formation will be both with electron microscope and confocal scanning laser microscope.

Condition	Intervention	Phase
Dental Plaque	Procedure: saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation	Phase I

MedlinePlus related topics:

Nuclear Scans

ChemIDplus related topics:

Chlorhexidine Chlorhexidine digluconate D-Gluconic acid, monosodium salt Gluconic acid Manganese gluconate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Non-Randomized, Single Blind, Uncontrolled, Single Group Assignment, Pharmacokinetics Study

Official Title:	Examination of the Immersion of Provisional Crown Material in Chlorhexidine Gluconate on Dental Plaque Formation in Vivo

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:

calibration of a preventative protocol for biofilm formation measured by confocal scanning laser microscope and scanning electron microscope

Estimated Enrollment:	12
Study Start Date:	January 2005

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Any volunteer without systemic condition

Exclusion Criteria:

Intake of antibiotic drug three months prior to experiment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00259181

Locations


Israel
	Hadassah Medical Organization
	Jerusalem, Israel, 91120

Sponsors and Collaborators

Hadassah Medical Organization

Investigators


Study Director:	Michael M Perez Davidi, DMD	Hadassah Medical Organization

More Information

Michael Perez Davidi This link exits the ClinicalTrials.gov site

Study ID Numbers:	191058HMO-CTIL
First Received:	November 24, 2005
Last Updated:	December 10, 2007
ClinicalTrials.gov Identifier:	NCT00259181
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Hadassah Medical Organization:

chlorhexidine gluconate

polymethylmethacrylate

Anti-Bacterial Agents

Study placed in the following topic categories:

Polymethyl Methacrylate

Tooth Diseases

Chlorhexidine

Chlorhexidine gluconate

Stomatognathic Diseases

Dental Plaque

Additional relevant MeSH terms:

Anti-Infective Agents

Anti-Infective Agents, Local

Disinfectants

Vasodilator Agents

Dental Deposits

Therapeutic Uses

Physiological Effects of Drugs

Antimutagenic Agents

Cardiovascular Agents

Dermatologic Agents

Protective Agents

Pharmacologic Actions

ClinicalTrials.gov processed this record on August 20, 2008